Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma

News provided by

www.aciassociation.com

Sep 22, 2015, 08:27 ET

NEW YORK, September 22, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.

AEterna Zentaris Inc.

AEterna Zentaris Inc.'s stock edged lower by 32.41% to close Monday's session at USD 0.08. The company's shares oscillated between USD 0.07 and USD 0.10. The stock recorded a trading volume of 130.53 million shares, which was above its 50-day daily average volume of 15.41 million shares. Over the last three days AEterna Zentaris Inc.'s shares have advanced 49.72% and in the past one week the stock has moved up 48.33%. On a compounded total return basis, the stock has shown a negative return of 20.77% in the past one month and of 71.70% in the past three months. The company is having a market capitalization of USD 9.45 million. The stock is trading at a price to book ratio of 1.31, while the historical PB ratio is near to 2.71. Additionally, the stock is trading at a price to sales ratio of 37.33. Sign up and read the free notes on AEZS at: http://www.aciassociation.com/AEZS.pdf

Great Basin Scientific Inc.

The stock of Great Basin Scientific Inc. gained 37.45% to close Monday's session at USD 0.07. The shares of the company moved in the range of USD 0.05 and USD 0.08. A trading volume of 121.09 million shares was recorded, which was greater than its 150-day daily average volume of 3.48 million shares and above its 52-week average volume of 2.20 million shares. Over the last five days Great Basin Scientific Inc.'s shares have declined by 18.25% and in the past one month the stock has lost 96.69%. The stock has shown a negative return of 97.98% in the past three months and of 96.62% in the last half year, on a compounded total return basis. Register for free on ACI Association and access the latest research on GBSN at: http://www.aciassociation.com/GBSN.pdf

Gilead Sciences Inc.

Gilead Sciences Inc.'s stock decreased by 2.49% to close Monday's session at USD 105.74. A total of 15.14 million shares exchanged hands, which surpassed its 50-day daily average volume of 10.80 million shares. Over the last three days Gilead Sciences Inc.'s shares have declined by 4.76% and in the past one week the stock has moved down 3.30%. The company has returned 0.61% in the past one month and 4.16% in the last half year, on a compounded total return basis. Gilead Sciences Inc. has a current dividend yield of 1.59%. The stock is trading at a price to earnings ratio of 11.10, compared to a historical PE ratio of 12.83. Further, the stock is at a price to book ratio of 9.56, while the historical PB ratio is near to 9.16. The complete research on GILD is available for free at: http://www.aciassociation.com/GILD.pdf

WaferGen Bio-systems Inc.

WaferGen Bio-systems Inc.'s stock added 90.06% to close Monday's session at USD 3.25. The company's shares oscillated between USD 1.71 and USD 3.47. The stock recorded a trading volume of 14.82 million shares, which was above its 50-day daily average volume of 0.49 million shares and above its 52-week average volume of 0.19 million shares. Over the last five days WaferGen Bio-systems Inc.'s shares have advanced 112.42% and in the past one month the stock has gained a momentum of 146.21%. In addition, over the last three months the stock has lost 12.87% and year to date the shares have picked up 8.33%. The company has returned 164.21% in the past one month and a negative return of 17.51% in the past three months, on a compounded total return basis. Free in-depth research on WGBS is available at: http://www.aciassociation.com/WGBS.pdf

Horizon Pharma PLC

Horizon Pharma PLC's stock declined 9.18% to close Monday's session at USD 28.99. The share price vacillated between USD 28.73 and USD 32.34. The stock recorded a trading volume of 8.24 million shares, which was above its 50-day daily average volume of 2.85 million shares. Over the last three days Horizon Pharma PLC's shares have advanced 0.28% but in the past one week the stock has moved down 0.10%. Moreover, in the last six months the stock has gained 30.94% and year to date the shares have picked up 124.90%. On a compounded total return basis, the company has returned 27.32% in the last half a year and 143.00% in the past one year. The stock is trading at a price to book ratio of 3.66, while the historical PB ratio is near to 2.98. Additionally, the stock is trading at a price to sales ratio of 7.92. The complimentary notes on HZNP can be downloaded in PDF format at: http://www.aciassociation.com/HZNP.pdf

About ACI Association:

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com